Bukwang stops marketing of clevudine tentatively

Published: 2009-04-23 06:58:00

Updated: 2009-04-23 06:58:00

Bukwang Pharm said it has voluntarily halted the marketing of Levovir (clevudine) for the treatment of chronic hepatitis B (HBV) infection as its US partner Pharmasset, Inc. decided to voluntarily terminate Phase III QUASH studies of clevudine on April 20.

Pharmasset recently became aware of a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK